chloasma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Compliance with the "Diagnostic and Therapeutic Criteria for Melasma and Vitiligo (2010 Edition)" formulated by the Pigmentary Disorders Study Group of the Dermatological and Venereal Diseases Professional Committee of the China Association of Integrative Medicine [6]: The skin lesion presents as light brown to dark brown patches on the face usually symmetrically distributed without inflammatory manifestations or scales; the condition may be seasonal often worse in summer and lighter in winter; exclusion of post-inflammatory hyperpigmentation naevus fusco-caeruleus zygomaticus Riehl's melanosis pigmented lichen planus and other skin diseases. (2) Female; aged 20 to 55 years; disease duration of 0.5 to 10 years. (3) No mental disorders affecting cognitive function with good communication skills. (4) Ability to adhere to the planned course of treatment and comply with lifestyle guidance recommendations regarding sun protection. (5) Patients have read and signed the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Age 55 years; (2) Women who are preparing for pregnancy, pregnant, or taking oral contraceptives; (3) Having taken other drugs affecting endocrine function within the past six months; (4) Suffering from serious primary diseases of the heart, liver, kidney, or hematopoietic system, or mental illness; (5) Known allergy to any component of the trial drug. (6) Failure to comply with or interruption of the treatment protocol of this trial; (7) Failure to meet the above inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melasma Area and Severity Index(MASI); | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology life quality index;TCM symptom integral table;Physician's Global Assessment (PGA);Patient Global Assessment (PtGA) ; | — |
Countries
China
Contacts
Beijing Aerospace General Hospital